Clinical Trial

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Study acronym: cAPPricorn-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2024-04-26; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2024-05-09
Trial Details
NCT Number NCT06393712
Lead Sponsor Alnylam Pharmaceuticals
Conditions Cerebral Amyloid Angiopathy
Enrollment 200 participants
Start Date 2024-05-17
Primary Completion 2027-08-09 (estimated)
Study Completion 2029-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-15